

Appendix C

Acknowledgements

In addition to the workshop participants listed in appendix B, the following people provided valuable guidance to the OTA staff.

Kathleen Buto
Health Care Financing
Administration
Bureau of Policy Development
Baltimore, MD

Regis A. de Silva
Harvard Medical School
Boston, MA

Paul Eggers
Health Care Financing
Administration
Office of Research and
Demonstrations
Baltimore, MD

Bruce Eisen
Genetics Institute, Inc.
Cambridge, MA

Joseph Eschbach
University of Washington
School of Medicine
Seattle, WA

Roger Evans
Batelle Research Center
Seattle, WA

Frank Gotch
Davies Medical Center
San Francisco, CA

Marlene Haffner
Food and Drug Administration
Office of Orphan
Products Development
Rockville, MD

Richard Husk
Health Care Financing
Administration
Office of Peer Review
Baltimore, MD

Paul Jeffrey
University of Maryland Hospital
Department of Pharmacy
Baltimore, MD

David Knapp
University of Maryland
School of Pharmacy
Baltimore, MD

Gary Kramer
Department of Health and
Human Services
Office of the Inspector General
Baltimore, MD

Steven Lawton
Reed, Smith, Shaw, and McClay
Washington, DC

Andreas Leupacis
University Hospital
Department of General Internal
Medicine
London, Ontario, Canada

Nathan Levin
Beth Israel Medical Center
New York, NY

Jeffrey McCombs
University of Southern California
School of Pharmacy
Los Angeles, CA

Paul Mendelson
Health Care Financing
Administration
ESRD Network Administration
Branch
Baltimore, MD

Alan Nissenson
University of California
at Los Angeles Medical Center
Los Angeles, CA

John Ogden
U.S. Department of Veterans
Affairs
Department of Pharmacy Services
Washington, DC

Emil Paganini
Cleveland Clinic Foundation
Cleveland, OH

Joseph Polastri
McKesson Drug Company
San Francisco, CA

Neil Powe
The Johns Hopkins University
School of Medicine
Baltimore, MD

Lisa Raines
Industrial Biotechnology
Association
Washington, DC

Kathleen Retterson
Amgen, Inc.
Thousand Oaks, CA

Dennis Revicki
BatelleResearch Center
Washington, DC

Elizabeth Rothberg
Health Insurance Association
of America
Washington, DC

John Sadler
Independent Dialysis Foundation
Baltimore, MD

Bernadette Schumaker
Health Care Financing
Administration
Office of ESRD Payment Policy
Baltimore, MD

Larry Simmons
Department of Health and
Human Services
Office of the Inspector General
Baltimore, MD

Dennis Styrsky
U.S. Department of Veterans
Affairs
Marketing Center
Hines, IL

Thomas Taylor
The Upjohn Company
Kalamazoo, MI

Wayne M. Turner
Food and Drug Administration
Office of orphanProducts
Development
Rockville, MD

Anne Vickery
Hogan and Hartson
Washington, DC

ADVISORY PANEL ON MEDICARE'S PRESCRIPTION DRUG BENEFIT: ALTERNATIVE PAYMENT POLICIES

Harold Cohen, *Panel Chair*
Harold Cohen, Inc.
Baltimore, MD

Lowell Anderson
Watauga Corporation
St. Paul, MN

Patricia A. Bell
Marriott Corporation
Washington, DC

Orson Berry
Arkansas Health
Services Agency
Little Rock, AR

Leonard J. DeMino
National Association
of Chain Drug Stores
Alexandria, VA

Arnold M. Epstein
Harvard Medical School
and School of Public Health
Boston, MA

Mark C. Hornbrook
Kaiser Permanence
Portland, OR

Ronald Jordan
Blue Cross/Blue Shield
of Rhode Island
Providence, RI

Thomas Kellenberger
PCS, Inc.
Scottsdale, AZ

Kenneth Larsen
Zetachron, Inc.
St. College, PA

Sidney S. Lee
Harvard Medical School
Department of Social Medicine
Boston, MA

Helene Lipton
University of California
Schools of Medicine and Pharmacy
San Francisco, CA

Patrick McKercher
The Upjohn Company
Kalamazoo, MI

Carlo Michelotti
California Department
of Health Services
Sacramento, CA

Marilyn Moon
The Urban Institute
Washington, DC

Michael Pollard
Michaels & Wishner
Washington, DC

Mark A. Pulido
Redline Medical Supply
Minneapolis, MN

Alice Rivlin
The Brookings Institution
Washington, DC

Gary J. Sekulski
Medco Containment
Services, Inc.
Fairlawn, NJ

Joseph Thomas
Purdue University
School of Pharmacy
West Lafayette, IN

Sidney Wolfe
Public Citizen Health
Research Group
Washington, DC

Advisory Panel members provide valuable guidance during the preparation of OTA reports. The presence of an individual on the Advisory Panel, however, does not mean that the individual agrees with or endorses the conclusions of this particular Report.